[1]
|
Editorial Committee on Japanese Guideline for Prevention of Venous Thromboembolism, “Japanese Guideline for Prevention of Venous Thromboembolism, Guideline 1-19,” Medical Frontier International Limited, Tokyo, 2006.
|
[2]
|
Agency for Health and Quality, “Reducing the risk of Thromboembolism during Pregnancy, Birth and the Puerperium,” Royal College of Obstetricians and Gynaecologists, London, Green-Top Guideline No. 37, 2009.
|
[3]
|
C. M. Samama, “Venous Thromboembolism Prevention in Surgery and Obstetrics: Clinical Guidelines,” European Journal of Anaesthesiology, Vol. 23, No. 2, 2006, pp. 95-116.
|
[4]
|
M. Blondon, A. Perrier, M. Nendaz, M. Righini, F. Boehlen, M. Boulvain and P. De Moerloose, “Thromboprophylaxis with Low-Molecular-Weight Heparin after Cesarean Delivery,” Journal of Thrombosis and Haemostasis, Vol. 103, No. 1, 2009, pp. 129-137.
doi:10.1160/TH09-06-0349
|
[5]
|
E. Forsnes, A. Occhino and R. Acosta, “Spontaneous Spinal Epidural Hematoma in Pregnancy Associated with Using Low Molecular Weight Heparin,” Obstetrics & Gynecology, Vol. 113, No. 2, 2009, pp. 532-533.
|
[6]
|
J. I. Weitz, J. Hirsh and M. M. Samansa, “New Anticoagulant Drugs,” Chest, Vol. 126, No. S3, 2004, pp. 265- 286. doi:10.1378/chest.126.3_suppl.265S
|
[7]
|
F. B. Robert, T. G. Eng, S. G. Alexander, M. W. Euan and A. B. Elizabeth, “A Randomized Double-Blind Placebo Controlled Trial of Low Molecular Weight Heparin as Prophylaxis in Preventing Venous Thrombolic Events after Cesarean Section: A Pilot Study,” British Journal of Obstetrics and Gynaecology, Vol. 108, No. 8, 2001, pp. 835-839.
|
[8]
|
European Fraxiparin Study Group, “Comparison of a Low Molecular Weight and Unfractionated Heparin for the Prevention of Deep Vein Thrombosis in Patients Undergoing Abdominal Surgery,” British Journal of Surgery, Vol. 75, No. 11, 1988, p. 1058.
doi:10.1002/bjs.1800751105
|
[9]
|
M. Koller, U. Schoch, P. Buchmann, F. Largiader, A. von Falten and P. G. Frick, “Low Molecular Weight Heparin (Kabi 2165) as Thromboprophylaxis in Electine Visceral Surgery: A Randomized, Bouble-Blind Study Versus Unfractionated Heparin,” Journal of Thrombosis and Haemostasis, Vol. 56, 1986, p. 243.
|
[10]
|
V. V. Kakkar, A. T. Cohen, R. A. Edmonson, M. J. Phillips, D. J. Cooper, S. K. Das, K. T. Maher, R. M. Sanderson, V. P. Ward and S. Kakkar, “Low Molecular Weight versus Standard Heparin for Prevention of venous Thromboembolism after Major Abdominal Surgery,” Lancet, Vol. 34, No. S4, 1993, pp. 259-265.
|
[11]
|
N. S. Fox, S. K. Laughon, S. D. Bender, D. H. Saltzman and A. Rebarber, “Anti-factor Xa Plasma Levels in Pregnant Women Receiving Low Molecular Weight Heparin Thromboprophylaxis,” Obstetrics & Gynecology, Vol. 112, No. 4, 2008, pp. 884-889.
doi:10.1097/AOG.0b013e31818638dc
|
[12]
|
J. Ellison, A. J. Thompson, J. A. Conkie, F. McCall, D. Walker and A. Greer, “Thromboprophylaxis Following Cesarean Section—A Comparison of the Antithrombolic Properties of Three Low Molecular Weight Heparins-Dalteparin, Enozaparin and Tinzaparin,” Journal of Thrombosis and Haemostasis, Vol. 86, No. 6, 2001, pp. 1374-1378.
|